Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wuhan Inst. of Technology XO compound 13i
- Development stage
- Unknown
- Lead developer
- Wuhan Institute of Technology
01
Overview
Wuhan Inst. of Technology XO compound 13i: sourced facts only. name: "Among the pyridazine derivatives, compound 13i exhibited the most potent XO inhibition (IC₅₀ = 0.20 μM) and was identified as a mixed-type inhibitor." [PMID:41101256]; target: "Among the pyridazine derivatives, compound 13i exhibited the most potent XO inhibition (IC₅₀ = 0.20 μM) and was identified as a mixed-type inhibitor." [PMID:41101256]; developer: "Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, PR China." [PMID:41101256]
Beyond the preview
Go deeper on Wuhan Inst. of Technology XO compound 13i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wuhan Inst. of Technology XO compound 13i.